Litcius/Paper detail

Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus—Safety Lead-in Results of a Phase 2 Trial

Vitaly Margulis, Yuval Freifeld, Laurentiu M. Pop, Subrata Manna, Payal Kapur, Iván Pedrosa, Alana Christie, Osama Mohamad, Samantha Mannala, Nirmish Singla, Michael A. Wait, Aditya Bagrodia, Solomon L. Woldu, Jeffrey Gahan, James Brugarolas, Robert Timmerman, Raquibul Hannan

2021International Journal of Radiation Oncology*Biology*Physics72 citationsDOIOpen Access PDF

Topics & Concepts

MedicineRenal cell carcinomaInferior vena cavaSABR volatility modelRadiologyThrombusCarcinomaCardiologyInternal medicineUrologyStochastic volatilityVolatility (finance)EconomicsFinancial economicsRenal cell carcinoma treatmentCardiac tumors and thrombiBladder and Urothelial Cancer Treatments
Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus—Safety Lead-in Results of a Phase 2 Trial | Litcius